22 November 2019 : Letter/Correspondence
Ann Transplant 2019; 24:605-607
The safety profile of rATG is impressive, with its use in 40% of inductions in living donor transplants in the US, with a reduced incidence of acute rejection, a low incidence of CMV infections with universal prophylaxis and enabling steroid sparing regimes.
Keywords: Graft Rejection, Immunosuppressive Agents, Kidney Transplantation, Antilymphocyte Serum
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588